Cardio D&R s.r.o. Kosice

The Cardio D&R s.r.o. Kosice site is strongly focused on cardiovascular research, with studies centered on atherosclerotic cardiovascular disease, heart failure, hypertension, and broader cardiovascular risk. These trials are mainly designed to test new treatments and assess whether they can better prevent major heart and stroke events, improve symptoms, and reduce complications.

• Prevention of major cardiovascular events in people with established or high-risk ASCVD
• New approaches for heart failure, including patients with reduced, preserved, or mildly reduced ejection fraction
• Studies for difficult-to-control hypertension and blood pressure reduction
• Evaluation of therapies targeting lipids, LDL-C, and lipoprotein(a)

Overall, the program at this hospital-based clinic in Košice is aimed at improving long-term cardiovascular outcomes through better prevention, symptom control, and risk reduction.

Another important research area at the site is nutritional and metabolic disease, especially conditions linked to obesity, overweight, type 2 diabetes, and metabolic syndrome. The trials in this field are largely exploring whether new therapies can improve weight management and help lower cardiovascular risk in people with metabolic disorders.

• Studies in adults with type 2 diabetes and/or metabolic syndrome plus elevated cholesterol
• Research on obesity and overweight as drivers of heart and metabolic complications
• Trials assessing whether new treatments can reduce body weight and improve overall cardiometabolic health
• Combined care strategies for patients with overlapping metabolic and cardiovascular risk

These studies reflect a practical effort to address metabolic conditions that often contribute to future heart disease and related complications.

The site also participates in research related to hemic and lymphatic diseases, with a particular emphasis on abnormal blood fats such as severe hypertriglyceridemia and elevated lipoprotein(a). The main purpose of these trials is to evaluate whether new therapies can improve lipid levels and lower the chance of future cardiovascular events.

• Treatment studies for severe hypertriglyceridemia and dyslipidemia
• Research on inherited or high-risk cholesterol disorders such as heterozygous familial hypercholesterolaemia
• Trials targeting elevated Lp(a) to reduce cardiovascular risk
• Evaluation of therapies intended to improve LDL-C and broader lipid control

At Cardio D&R s.r.o. Kosice, this area of research is closely linked to prevention, with the goal of reducing long-term damage from persistent lipid abnormalities.

In respiratory research, the site is involved in studies of chronic obstructive pulmonary disease and related cardiopulmonary outcomes. These trials are designed to see whether new treatment combinations can improve breathing-related health while also lowering the risk of serious heart and lung complications.

• Research in COPD focused on better symptom control and outcome prevention
• Studies examining the interaction between lung disease and cardiovascular risk
• Evaluation of therapies intended to reduce severe cardiopulmonary events
• Support for patients with overlapping respiratory and cardiac conditions

This line of work highlights how the clinic’s research extends beyond the heart to conditions that can strongly affect overall cardiopulmonary health.

The site’s research portfolio includes inherited and genetically influenced conditions, especially disorders that shape cholesterol metabolism and lifelong cardiovascular risk. These trials aim to test whether targeted therapies can better manage hereditary lipid disorders and prevent early disease progression.

• Studies in familial hypercholesterolaemia and other inherited lipid disorders
• Research focused on reducing long-term risk in patients with genetic cardiovascular conditions
• Evaluation of therapies for people with high bad cholesterol from inherited causes
• Prevention-oriented trials for patients with early-onset or lifelong atherosclerotic risk

These investigations support more personalized care for patients whose disease risk is driven by hereditary factors rather than lifestyle alone.